

Special Issue

Oncogenes and Tumor Suppressor Genes in Brain Tumor

Message from the Guest Editor

Induction of oncogenes and absence of tumor suppressor genes would trigger certain cellular pathways that control cell cycle, cell survival, cell growth, with a direct link to tumorigenicity depending on the context. Developing an understanding about how different cell types regulate the expression of oncogenes and tumor suppressor genes is of important significance. This Special Issue will cover downstream signaling pathways for oncogenes and tumor suppressor genes, their upstream regulators, their control mechanisms (at the level of epigenetics, transcription, translation, protein homeostasis), and the outcome of their mutation affecting cellular survival, differentiation, and proliferation. While different primary or metastatic brain tumors will be considered, manuscripts focusing on medulloblastomas and gliomas are encouraged. In addition, manuscripts linking oncogenes and tumor suppressor genes to regulatory cellular mechanisms, such as proteasome pathway, cellular metabolism, and cell death machinery (including autophagy, apoptosis), are welcome for submission.

Guest Editor

Prof. Dr. Mojgan Rastegar

Department of Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R3E 0J9, Canada

Deadline for manuscript submissions

closed (30 April 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/88983

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)